Introduction
VTE
SEVERE OBESITY, POSTOPERATIVE COMPLICATION, SECONDARY, EVENTS, DRUG-DRUG INTERACTION
The epidemic increase in severe obesity and the effectiveness and safety of bariatric interventions (regarding body weight reduction and resolution of associated comorbidities as well as low postoperative complication rates) have led to a worldwide increase in the rate of bariatric surgery during the last few decades.All patients undergoing bariatric surgery are considered to be at least at moderate risk for VTE events because of severe obesity with associated comorbidities, laparoscopic surgery, and perioperative immobility.With the benefits of oral dosing, low drug-drug interaction potential, no known food interaction, and fixed dosing regimens, direct oral anticoagulants (DOACs) have expanded the spectrum of anticoagulants during the last several years. Once-daily oral rivaroxaban is approved for primary (and secondary) thromboprophylaxis in patients with elective hip or knee replacement surgery,The impact of bariatric surgery with a consecutively altered anatomy on pharmacokinetics and pharmacodynamics of a single prophylactic dose of rivaroxaban has been investigated in 2 previous phase 1 clinical trials.